Science Pool

Download this fact sheet to learn more about how Cyprotex can support you in assessing the clearance of your test article using our microsomal stability assay.

Through the use of liquid handling automation and high resolution mass spectrometry, high quality data is delivered rapidly to feed into drug discovery programs.

DOWNLOAD

Read about the newly adopted harmonized drug interaction guideline including:

• An overview of the key highlights of the new ICH M12 harmonized guideline on drug interaction studies (2024)
• A comparison with the Japanese PMDA guideline on drug interaction for drug development (2018)

LEARN MORE

Read about the newly adopted harmonized drug interaction guideline including:

• An overview of the key highlights of the new ICH M12 harmonized guideline on drug interaction studies (2024)
• A comparison with the EMA guideline on the investigation of drug interactions (2013)

LEARN MORE

The new ICH M12 guideline on drug interaction studies provides a harmonized approach expected to be implemented by the major regulatory authorities such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and presumably replace their respective existing guidance.

Explore the differences between the 2020 FDA Guidance and the 2024 ICH M12 Guideline with our handy reference document.

LEARN MORE

Evotec offers state-of-the-art mass spectrometry-based proteomics solutions to support drug development and biomarker discovery. Our ScreenPep™ platform enables high-throughput, automated plasma and serum proteomics with deep coverage, identifying up to 1,000 proteins from minimal sample volumes. As Europe's exclusive provider of Proteograph™ technology, we can identify up to 5,000 proteins from human biofluids, enhancing biomarker discovery. Integrated with genomics, transcriptomics, and metabolomics data, Evotec's proteomics services offer a holistic approach to translational research.

With over 20 years of experience and advanced technologies like timsTOF and Orbitrap, Evotec delivers precise, comprehensive, and scalable proteomics solutions tailored to customer needs.
read out factsheet to learn more about our clinical proteomics and how we can support your drug development

Read it now!

Evotec specializes in antifungal drug discovery with a focus on WHO and CDC priority human pathogens such as Aspergillus fumigatus, Candida spp, and Cryptococcus neoformans. Their track record in late-stage drug discovery is proven, aided by a range of established in vivo models of fungal infection that facilitate seamless progression from in vitro to in vivo studies.

Their expertise encompasses various areas, including in vitro compound characterization, invasive and localized in vivo fungal infection models, PK/PD mathematical modeling, and custom assay development tailored to individual project needs. They conduct comprehensive antifungal susceptibility testing to industry standards and offer specialized modalities such as combination testing to determine synergy or antagonism.

DOWNLOAD NOW

This factsheet looks at deciphering the immunopeptidome for neoantigen identification. 

Download it here!

Our target deconvolution factsheet looks at the following areas:  

• Pioneered chemical proteomic applications
• Target selectivity profiling
• Evotec Cellular Target Profiling™
• Photoaffinity labelling coupled to MS
  
  
  

View it now!

Learn more about the Evotec's EvostrAln^TM, a comprehensive collection of diverse human pathogenic bacteria and fungi:

• ESKAPE pathogens
• Strains from the WHO priority pathogen lists
• Highly characterised and fully sequenced with defined MoR
  
  

Gene therapy has evolved as an attractive modality to tackle and/or even cure a broad range of diseases. EVOgenes is built on a team with long-standing pharma expertise in various gene therapy-related technologies and indications.

Take a look at our factsheet to discover the broad spectrum of state-of-the-art services enabling gene therapy product development we offer.